reports
- Bruno Bulic
H1 2024 results in-line with expectations
Abivax today reported H12024 results reporting a cash balance at EUR 222.3mn and a cash reach to Q4 2025, thereby reiterating preliminary figures provided last July. The EUR 85.2mn cash used in operation was principally driven by increased R&D spending (EUR 64.7mn) on the Phase III in UC (ABTEC
- Bruno Bulic
Abivax: ABTECT study enrollment on track
Abivax today provided an update on the enrollment status into its ABTECT phase III study, disclosing the enrollment of the 600th patient and confirms enrollment completion for Q1 2025 (read-out for Q2 2025).Good to know, Abivax confirmed that to date, baseline participants baseline characteristics
- Bruno Bulic
Abivax minor Ph. III read-out delay
Yesterday after close, Abivax provided an update on the enrollment status into its ABTECT phase III study, disclosing a single quarter delay in the expected read-out, now scheduled for Q2 2025. Considering the complexity of the study (600 sites, 1,200 patients) we do not see any red flags in such m
- Bruno Bulic
Abivax KOL takeaways: uniquely differentiated
We hosted a KOL call focused on Obefazimod (Abivax) with Prof. Yoram Bouhnik, head of the Paris IBD center and author of over 300 peer-reviewed publications on IBD. Prof. Bouhnik, participated in Obefazimod Phase IIb (11 patients enrolled) and in current Phase III (17 enrollees).Key takeaways from
- Healthcare Team
- Oscar Haffen Lamm
Abivax: reports FY 2023 and reiterates timelines
Abivax reported its FY 2023 financial results, which highlighted the total EUR 500m raised in 2023 (incl. EUR 130m capital increase, two structured debt financing transactions aggregating EUR 150m and EUR 223.3m US IPO). In particular, the financial results highlighted i) operating loss at EUR -127
- Oscar Haffen Lamm
Takeaways from the KOL event
Abivax hosted a virtual KOL event yesterday featuring i) a discussion on the unmet medical need and current treatment landscape for patients with UC, and ii) a review of Obefazimod's phase 2b data as well as iii) the phase 3 trial design for the treatment of moderate-to-severe UC and its strategy t
- Maria Vara
- Oscar Haffen Lamm
Coverage update
Given team and strategy changes, Oscar Haffen Lamm is now assuming coverage of Medincell, Camurus, Valneva, Aelis Pharma, Abivax, Calliditas, Egetis Therapeutics, Basilea, Geneuro, Achilles, Valerio, Innate Pharma, Morphosys, Inventiva Pharma, Vicore, DBV Technologies, and Genfit.Maria Vara is now
BSLN BASILEA PHARMACEUTICA AG
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
ALMDT MEDIAN TECHNOLOGIES
EGTX EGETIS THERAPEUTICS AB
7CA CAMURUS AB
VICO VICORE PHARMA HOLDING AB
5142 ACHILLES CORP.
A3TV ATRESMEDIA CORPORACION DE MEDIOS DE COMUNICACION SA
XVIVO XVIVO PERFUSION AB
GNRO GENEURO SA
BONEX BONESUPPORT HOLDING AB
MOR MORPHOSYS AG
MED MEDARTIS AG
MEDCL MEDINCELL SA
CALTX CALLIDITAS THERAPEUTICS AB
IVA INVENTIVA ADS
CLNK B CELLINK AB
GNFT GENFIT
AELIS AELIS FARMA SA
ONWD ONWARD OPPORTUNITIES LIMITED
ALONX ONXEO
ABVX ABIVAX
- Alex Cogut
- Oscar Haffen Lamm
The path is all clear to deliver the next big drug in IBD, raising our...
Following the recent US IPO, Abivax is well financed to execute its clinical plan with obefazimod with the induction topline results from its phase 3 program in ulcerative colitis expected in Q1 2025. Additionally, we expect the start of a phase 2a study with obefazimod in Crohn's disease to kick o
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.